• Corpus ID: 14890139

Selective COX-2 Inhibitors and Risk of Cardiovascular Events

  title={Selective COX-2 Inhibitors and Risk of Cardiovascular Events},
  author={Gilad Segev and Richard J. Katz},
  journal={Hospital physician},
onsteroidal anti-inflammatory drugs (NSAIDs) are prescribed commonly for the treatment of pain and inflammation caused by various musculoskeletal disorders and dysmenorrhea. Nonselective NSAIDs’ anti-inflammatory effects appear to be caused by blocking the enzyme cyclooxygenase-2 (COX-2). In addition, nonselective NSAIDs exert both their antiplatelet and detrimental effects on the gastrointestinal mucosa by blocking COX-1. 1 COX-2 inhibitors were developed as a safer alternative to traditional… 

Figures from this paper

Cardiovascular Risks of Cyclooxygenase Inhibition
The pharmacologic and clinical evidence that defines the cardiovascular risk associated with COX inhibition is examined, finding that selective COX inhibitors provide more gastrointestinal protection than NSAIDs and the unbalanced inhibition of prostaglandins may promote cardiovascular complications.
Management of Chronic Nonmalignant Pain with Nonsteroidal Antiinflammatory Drugs
Evidence‐based use of NSAIDs for frequently encountered pain syndromes, with special focus on the adverse effects of this class of agents is evaluated by members of the Ambulatory Care, Cardiology, and Pain and Palliative Care Practice and Research Networks of the American College of Clinical Pharmacy.
Cardiovascular Events Associated with Long-Term Use of Celecoxib, Rofecoxib and Meloxicam in Taiwan
Patients taking celecoxib had a lower risk of cardiovascular events than those taking meloxicam, and patients taking rofecoxib were not found to be at higher cardiovascular risk than thoseTakingmeloxicam.
Cardiovascular Effects of COX-2 Inhibitors: A Review of the Literature
The reader should be able to understand the possible mechanisms of action for the cardiovascular side effects of the various COX-2 inhibitors and identify which patients are appropriate for COx-2s.
Folic acid ameliorates celecoxib cardiotoxicity in a doxorubicin heart failure rat model
Folic acid protects against the cardiotoxic effects of celecoxib, which are aggravated in the presence of doxorubicin, and may act as a useful adjunct in patients who are taking Celecoxib.
Pharmacological evaluation of South African medicinal plants used for treating tuberculosis and related symptoms.
The author explains how the characters, plots, and characters in the novel changed during the course of the story changed over time from those described in the first chapter to those in the second.
Complementary treatment in endometriosis
W przypadku endometriozy dieta, suplementacja witamin oraz mikroi makroelementów jest istotna zarówno jako czynnik ryzyka wystąpienia choroby, jak i element terapii uzupełniającej.


Risk of cardiovascular events associated with selective COX-2 inhibitors.
The results from VIGOR showed that the relative risk of developing a confirmed adjudicated thrombotic cardiovascular event with rofecoxib treatment compared with naproxen was higher than that in the placebo group of a recent meta-analysis of 23 407 patients in primary prevention trials.
The double-edged sword of COX-2 selective NSAIDs.
  • James M. Wright
  • Medicine
    CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne
  • 2002
Proof that the increased harm was not caused by the COx-2 selectivity of the drugs depends on demonstration in a randomized controlled trial that COX-2 selective NSAIDs at usual doses are as effective as nonselective NSAIDs and cause fewer gastrointestinal serious adverse events without increasing the incidence of total nongastrointestinalserious adverse events.
Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study.
In this study, celecoxib, at dosages greater than those indicated clinically, was associated with a lower incidence of symptomatic ulcers and ulcer complications combined, as well as other clinically important toxic effects, compared with NSAIDs at standard dosages.
Nitric Oxide, Anti-Inflammatory Drugs on Renal Prostaglandins and Cyclooxygenase-2
It is reported here that both a nonselective NSAID (aspirin, acetylsalicylic acid) and COX-2 selective NSAIDs diminished renal prostacyclin and thromboxane concentration in the renal medulla.
Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics, and vasoactive eicosanoids.
The data suggest that acute sodium retention by nonsteroidal anti-inflammatory drugs in healthy elderly subjects is mediated by the inhibition of Cox-2, whereas depression of GFR is due to inhibition ofcox-1.
Thrombosis in patients with connective tissue diseases treated with specific cyclooxygenase 2 inhibitors. A report of four cases.
4 patients with connective tissue diseases who developed ischemic complications after receiving celecoxib are described, suggesting that COX-2 inhibitor-treated patients with diseases that predispose to thrombosis should be monitored carefully for this complication.
Basic biology and clinical application of specific cyclooxygenase-2 inhibitors.
Clinical trials demonstrate the potential for clinically meaningful reductions in the incidence of the most serious GI complications found with nonselective NSAIDs, i.e., ulcer, perforation, and GI bleeding.
Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group.
In patients with rheumatoid arthritis, treatment with rofecoxib, a selective inhibitor of cyclooxygenase-2, is associated with significantly fewer clinically important upper gastrointestinal events than treatment with naproxen, a nonselective inhibitor.
Effects of Selective Cyclooxygenase-2 Inhibition on Vascular Responses and Thrombosis in Canine Coronary Arteries
The results indicate important physiological roles for COX-2–derived prostacyclin and raise concerns regarding an increased risk of acute vascular events in patients receiving COx-2 inhibitors, which may be increased in individuals with underlying inflammatory disorders.